Publications

Management of
infectious diseases

Alt tag

Publications

See the recommendations from the steering committee members of their must-read papers on the management of infectious diseases.

Dispensing of antibiotics without a prescription: a worldwide problem

Batista AD, et al. Antibiotics 2020;9:786 doi: 10.3390/antibiotics9110786

View now
Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections

Bassetti M, et al. Int J Antimicrob Agents 2020;56: 106184, published online 9 October 2020. doi: 10.1016/j.ijantimicag.2020.106184.

View now
Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection.

Dong Y-H, et al. JAMA Intern Med 2020 Sep 8 doi:10.1001/jamainternmed.2020.4192.

View now
Association of fluoroquinolones with the risk of aortic aneurysm or aortic dissection.

Gopalakrishnan C, et al. JAMA Intern Med 2020 Sep 8 doi:10.1001/jamainternmed.2020.4199

View now
Observational study design challenges – the case of fluoroquinolones and aortic disease.

DeGette RL, et al. JAMA Intern Med 2020 Sep 8 doi:10.1001/jamainternmed.2020.4191 

View now
Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis.

De Jonge SW, et al. Lancet Infect Dis 2020;20:1182–92

View now
Effect of tolerance on the evolution of antibiotic resistance under drug combinations.

Liu J, et al. Science 2020;367:200–4. 

View now
Resistance-guided treatment of gonorrhea: a prospective case study.

Klausner JD, et al. Clin Infect Dis 2020 Aug 7;ciaa596. doi: 10.1093/cid/ciaa596

View now

If you have observed any unwanted or adverse effect, or have a quality complaint related to a Bayer product, we would be interested to hear about it as part of our ongoing pharmacovigilance processes. You may report these to us through our Bayer Side Effect Reporting website.